Aim Immunotech Stock Investor Sentiment

AIM Stock  USD 8.40  0.01  0.12%   
About 72 percent of all AIM ImmunoTech's investors are curious in acquiring. The analysis of the overall investor sentiment regarding AIM ImmunoTech suggests that many traders are confidant. AIM ImmunoTech's investing sentiment overview a quick insight into current market opportunities from investing in AIM ImmunoTech. Many technical investors use AIM ImmunoTech stock news signals to limit their universe of possible portfolio assets and to time the market correctly.

AIM ImmunoTech Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards AIM ImmunoTech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of AIM ImmunoTech's Stock prices. Below is the latest headlines and news related to AIM ImmunoTech Stock. The global stock market is bearish. About 68% of major world exchanges and indexes are down. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about AIM ImmunoTech that are available to investors today. This information is accessible both publicly - through AIM ImmunoTech's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of AIM-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of AIM ImmunoTech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AIM ImmunoTech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AIM ImmunoTech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AIM ImmunoTech alpha.

AIM Largest EPS Surprises

Earnings surprises can significantly impact AIM ImmunoTech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-05-13
2022-03-31-0.07-0.08-0.0114 
2021-11-15
2021-09-30-0.07-0.08-0.0114 
2021-05-17
2021-03-31-0.09-0.080.0111 
2020-08-14
2020-06-30-0.1-0.11-0.0110 
2021-03-31
2020-12-31-0.07-0.09-0.0228 
2023-05-15
2023-03-31-0.11-0.080.0327 
View All Earnings Estimates
3 days ago at globenewswire.com         
Cornish Metals Provides an Activities Update for the South Crofty Tin Project
Macroaxis News: globenewswire.com
3 days ago at simplywall.st         
Even With A 30 percent Surge, Cautious Investors Are Not Rewarding Ai-Media Technologies Limiteds Pe...
Simply Wall St News at Macroaxis
over a week ago at www.macroaxis.com         
Insider Trading
Macroaxis News
over a week ago at businesswire.com         
AIM Sports Group Names Chris Hoppe Executive Vice President
businesswire News
over a week ago at eu-startups.com         
Prague-based Aim wants to kill your information overload and just raised 300k to do it
news
over a week ago at prnewswire.com         
AIM Academy Awarded Alabama First Class Pre-K Expansion Classrooms for 2025-2026 School Year
prnewswire News
over two weeks ago at prnewswire.com         
AIM B2B Launches in Tokyo to Transform B2B Marketing in Asia
prnewswire News
over two weeks ago at globenewswire.com         
Cornish Metals Announces Exercise of Stock Options and Issue of Equity
Macroaxis News: globenewswire.com
over two weeks ago at businesswire.com         
AIM Sports Group Teams with BASE Sports Group to Power and Elevate the Next Generation of Youth Spor...
businesswire News
over two weeks ago at businesswire.com         
OBERON AIM VCT PLC UK Regulatory Announcement Holding in Company
businesswire News
over two weeks ago at prnewswire.com         
Truv Now Offers Automated Asset Verification Through Freddie Mac Loan Product Advisor as an AIM Serv...
prnewswire News
over three weeks ago at businesswire.com         
OBERON AIM VCT PLC UK Regulatory Announcement Holding in Company
businesswire News
over three weeks ago at gurufocus.com         
AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships ...
Gurufocus Stories at Macroaxis
over three weeks ago at globenewswire.com         
AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the...
Macroaxis News: globenewswire.com
over three weeks ago at simplywall.st         
ASX Penny Stock Highlights Ai-Media Technologies And Two Other Noteworthy Picks
Simply Wall St News at Macroaxis
There is far too much social signal, news, headlines, and media speculation about AIM ImmunoTech that are available to investors today. This information is accessible both publicly - through AIM ImmunoTech's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of AIM-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of AIM ImmunoTech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AIM ImmunoTech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AIM ImmunoTech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AIM ImmunoTech alpha.

AIM ImmunoTech Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists
05/08/2025
2
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
06/12/2025
3
Acquisition by Thomas Equels of 107 shares of AIM IMMUNOTECH at 7.697 subject to Rule 16b-3
06/13/2025
4
OBERON AIM VCT PLC UK Regulatory Announcement Issue of Equity
06/20/2025
5
Acquisition by Stewart Appelrouth of 24452 shares of AIM IMMUNOTECH at 0.213 subject to Rule 16b-3
06/27/2025
6
ASX Penny Stock Highlights Ai-Media Technologies And Two Other Noteworthy Picks
07/01/2025
7
AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies
07/02/2025
8
AIM Sports Group Teams with BASE Sports Group to Power and Elevate the Next Generation of Youth Sports
07/09/2025
9
AIM B2B Launches in Tokyo to Transform B2B Marketing in Asia
07/11/2025
10
AIM Sports Group Names Chris Hoppe Executive Vice President
07/16/2025
11
Insider Trading
07/17/2025
12
Cornish Metals Provides an Activities Update for the South Crofty Tin Project
07/24/2025
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports:
Check out AIM ImmunoTech Hype Analysis, AIM ImmunoTech Correlation and AIM ImmunoTech Performance.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(24.00)
Revenue Per Share
0.238
Quarterly Revenue Growth
(0.60)
Return On Assets
(0.98)
Return On Equity
(31.39)
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.